Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example EvidenceVariable: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA

Generated Narrative: EvidenceVariable 236950

version: 67; Last updated: 2024-12-14 08:46:28+0000

Profile: GroupAssignment

url: https://fevir.net/resources/EvidenceVariable/236950

identifier: FEvIR Object Identifier/https://fevir.net/FOI/236950, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-group-assignment-85394-85798

name: GroupAssignment_SGLT2_inhibitors_vs_GLP_1_RA

title: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

This EvidenceVariable Resource is referenced in an example for the EBMonFHIR Implementation Guide.

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

author: Computable Publishing®: MAGIC-to-FEvIR Converter:

RelatedArtifacts

-TypeResourceReference
*Part OfMAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)

Definitions

-Concept
*Defined in handling and category elements

handling: dichotomous variable

category

name: SGLT2 inhibitors

value: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors

category

name: GLP-1 RA

value: Glucagon-Like Peptide-1 (GLP-1) receptor agonists